Chemical Namebelimumab
Dosage FormInjection (subcutaneous; 200 mg/mL); Injection (intravenous; 120 mg, 400 mg)
Drug ClassB-lymphocyte stimulator-specific inhibitors
Approval Year2011


  • For the treatment of patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
  • For the treatment of adult patients with active lupus nephritis who are receiving standard therapy.
Document TitleYearSource
Benlysta (belimumab) Prescribing Information.2022GlaxoSmithKline LLC, Philadelphia, PA
Document TitleYearSource
Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: a systematic review and meta-analysis of randomised controlled trials.2022International Immunopharmacology
Efficacy and safety of belimumab therapy in systemic lupus erythematosus: a systematic review and meta-analysis.2022Lupus
The role of belimumab in systemic lupus erythematosis: a systematic review.2022Cureus
Real-world effectiveness of belimumab in systemic lupus erythematosus: a systematic literature review.2022Rheumatology and Therapy
Belimumab for treating active autoantibody-positive systemic lupus erythematosus.2021NICE
Belimumab and voclosporin for lupus nephritis: effectiveness and value.2021ICER
Assessment report: Benlysta.2021EMA
Belimumab in lupus nephritis: a systematic review and meta-analysis.2021Cureus
Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials.2021Lupus Science & Medicine
Belimumab for systemic lupus erythematosus.2021Cochrane Database of Systematic Reviews
Clinical review report: belimumab.2020CADTH
Management of cutaneous manifestations of lupus erythematosus: a systematic review.2020Seminars in Arthritis and Rheumatism
Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders.2020Allergy
Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus.2018Seminars in Arthritis and Rheumatism
Drug updated on 5/29/2023

More on this drug: Clinical Trials